publication venue for
- Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada 2024
- Dual-specific T Cells: Combining Car-engineered T Cells With Oncolytic Virotherapy 2012
- Rapamycin Treatment Endows Car-engineered CD8+Effector T Cells With Memory-like Properties Resulting in Enhanced in vivo Engraftment 2012
- Development of a Novel Chimeric Antigen Receptor Targeting the Melanoma Antigen GP75 2010
- Investigating the Impact of Autophagy Modulation on Dendritic Cell Cancer Vaccines 2010
- Cytotoxic therapies can enhance the efficacy of therapeutic cancer Vaccines but the outcome remains limited by antigen selection and the development of antigen-loss variants 2007
- Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases. 44:362-370. 2021
- Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma. 44:167-174. 2021
- Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer. 44:41-48. 2021
- Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. 41:64-72. 2018
- Identification of Synthetic Peptides that Inhibit Lipopolysaccharide (LPS) Binding to Myeloid Differentiation Protein-2 (MD-2). 36:197-207. 2013
- A NOVEL TRANSFORMING GROWTH FACTOR IS PRESENT IN MALIGNANT ASCITES FROM HUMAN OVARIAN CARCINOMA. 14:359-359. 1993
- In Vivo Antitumor Efficacy of Tumor-Draining Lymph Node Cells Activated with Nonspecific T-Cell Reagents. 14:279-285. 1993
- TRANSFORMING GROWTH FACTOR-BETA IS PRESENT IN ACTIVE FORM IN ASCITIC FLUID FROM HUMAN OVARIAN CARCINOMA. 13:61-61. 1993